Following the completion of the transaction, LifeCell will operate as a new global biosurgery division within KCI. Paul Thomas will continue to lead the business as President of the division and will join KCI’s Executive Committee. LifeCell’s management team and corporate headquarters will continue to be located in Branchburg, New Jersey. Based on existing KCI and LifeCell operations, the combined companies are expected to generate revenue of approximately $2 billion in 2008 and will employ more than 7,000 people.
“This is an exciting day for KCI,” said Catherine Burzik, President and Chief Executive Officer of KCI. “LifeCell is an exceptional strategic fit for us. The acquisition of LifeCell provides additional long-term growth opportunities, benefiting patients and physicians and delivering sustained value to our shareholders. The acquisition brings together two respected market leaders with well-established best-in-class technologies. This combination allows us to accelerate our strategy to increase KCI’s presence in the operating room and will leverage our broad global market reach to drive future growth of LifeCell’s products. The focus of the integrated management team will be to bring to market unparalleled therapeutic solutions for patients. I am confident that the combined company will be a powerful force in delivering advanced therapies for complex clinical situations. We admire the achievements of Paul Thomas and his management team and look forward to welcoming LifeCell’s world-class sales force and product development organizations to KCI where they will play a crucial role in our future success.”buy lifecell cream like with any skin care regimen, you have to be diligent.?This is doubly true with anti-wrinkle treatments.?The wrinkles didn’t get there overnight so it can take many months to start to see visible results.?However, with lifecell Skin Cream you just have to get through the first month, and they’re saying that you should see enough of a difference to keep yourself motivated and to buy a full supply and continue on with the program.
“Our board of directors and management team believe this transaction makes strategic sense for our company, offers a premium to our stockholders and creates exciting opportunities for our employees,” said Paul Thomas, Chairman of the Board, President and Chief Executive Officer of LifeCell. “We expect that the combination of our leadership position in regenerative medicine and KCI’s innovative therapeutic approach to wound healing will present opportunities for both organizations to expand the markets we serve. KCI’s global infrastructure will accelerate the penetration of LifeCell products into international markets. We also believe KCI’s experience and leadership position in advanced wound care will facilitate the adoption of LifeCell’s innovative products into this market. Together, we look forward to improving the lives of more patients around the world.”